Amrize's 15min Chart: MACD Death Cross, Bollinger Bands Narrowing Indicators

Amrize's 15-minute chart has recently exhibited a MACD Death Cross and Bollinger Bands Narrowing at 10:45 on October 10, 2025. This indicates that the stock price is poised to continue its downward trajectory, with the magnitude of fluctuations in the stock price decreasing.

Amrize Inc. (AMRZ.US) has recently experienced a significant shift in its stock price dynamics, with a MACD Death Cross and Bollinger Bands Narrowing observed at 10:45 on October 10, 2025. This technical indicator combination suggests that the stock price is poised to continue its downward trajectory, with decreasing volatility in price fluctuations.

Analyst Timna Tanners of Wells Fargo initiated coverage on Amrize with a buy rating and a target price of $57, as reported by TipRanks Wells Fargo Initiates Amrize(AMRZ.US) With Buy Rating, Announces Target Price $57^[1]. However, the stock has been volatile, dropping 9.0% over the last month and 16.4% year-to-date. This price movement has been influenced by broader market shifts and changing sector sentiment rather than company-specific catalysts.

A deeper analysis using the Discounted Cash Flow (DCF) model suggests that Amrize is significantly undervalued, with an estimated intrinsic value of $75.07 per share, indicating a 48.7% discount from its current market price Does Amrize’s Discounted Price in 2025 Reflect Its True Value After Recent Market Moves?^[2]. Despite this valuation, the stock has shown a lack of investor confidence, with a Price-to-Earnings (PE) ratio of 22.6x, which is close to the industry average but commands a premium relative to the broader Basic Materials sector.

Amrize is scheduled to release its third quarter 2025 financial results after the U.S. market closes on October 28, 2025, followed by a live webcast at 9:00 am Eastern Time on October 29, 2025 Amrize Announces Date for Third Quarter 2025 Financial Results^[3]. Investors are encouraged to monitor these updates closely, as they may provide further insights into the company's financial health and future prospects.

In conclusion, while the analyst rating and technical indicators present a mixed picture, the current stock price dynamics and valuation suggest a cautious outlook for Amrize. Investors should closely follow the upcoming financial results and consider the broader market conditions when making investment decisions.